» Articles » PMID: 17025248

Thermoreversible-mucoadhesive Gel for Nasal Delivery of Sumatriptan

Overview
Publisher Springer
Specialty Pharmacology
Date 2006 Oct 10
PMID 17025248
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of the present study was to develop intranasal delivery systems of sumatriptan using thermoreversible polymer Pluronic F127 (PF127) and mucoadhesive polymer Carbopol 934P (C934P). Formulations were modulated so as to have gelation temperature below 34 degrees C to ensure gelation at physiological temperature after intranasal administration. Gelation temperature was determined by physical appearance as well as by rheological measurement. The gelation temperatures of the formulations decreased by addition of increasing concentrations of Carbopol (ie, from 29 degrees C for 18% PF127 to 23.9 degrees C for 18% PF127, 0.5% Carbopol). The mucoadhesive force in terms of detachment stress, determined using sheep nasal mucosal membrane, increased with increasing concentration of Carbopol. The results of in vitro drug permeation studies across sheep nasal mucosa indicate that effective permeation coefficient could be significantly increased by using in situ gelling formulation with Carbopol concentration 0.3% or greater. Finally, histopathological examination did not detect any damage during in vitro permeation studies. In conclusion, the PF127 gel formulation of sumatriptan with in situ gelling and mucoadhesive properties with increased permeation rate is promising for prolonging nasal residence time and thereby nasal absorption.

Citing Articles

Investigation of a Thermoresponsive In Situ Hydrogel Loaded with Nanotriphala: Implications for Antioxidant, Anti-Inflammatory, and Antimicrobial Therapy in Nasal Disorders.

Phongpradist R, Chittasupho C, Singh S, Ontong J, Tadtong S, Akachaipaibul P Gels. 2025; 11(2).

PMID: 39996649 PMC: 11853876. DOI: 10.3390/gels11020106.


In Situ Thermosensitive Mucoadhesive Nasal Gel Containing Sumatriptan: and Evaluations.

Alshraim A, Alshora D, Ashri L, Alhusaini A, Alanazi N, Safwan N Polymers (Basel). 2024; 16(23).

PMID: 39684167 PMC: 11644292. DOI: 10.3390/polym16233422.


Suppression of virulence factors of uropathogenic Escherichia coli by Trans-resveratrol and design of nanoemulgel.

ElFeky D, Kassem A, Moustafa M, Assiri H, El-Mahdy A BMC Microbiol. 2024; 24(1):412.

PMID: 39415103 PMC: 11484331. DOI: 10.1186/s12866-024-03538-4.


Formulation and Characterization of Intranasal Drug Delivery of Frovatriptan-Loaded Binary Ethosomes Gel for Brain Targeting.

Layth Hamzah M, Kassab H Nanotechnol Sci Appl. 2024; 17:1-19.

PMID: 38249545 PMC: 10799622. DOI: 10.2147/NSA.S442951.


Formulation of Intranasal Mucoadhesive Thermotriggered In Situ Gel Containing Mirtazapine as an Antidepressant Drug.

Ghazwani M, Vasudevan R, Kandasamy G, Manusri N, Devanandan P, Puvvada R Gels. 2023; 9(6).

PMID: 37367128 PMC: 10297899. DOI: 10.3390/gels9060457.


References
1.
Lang S, Langguth P, Oschmann R, Traving B, Merkle H . Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. J Pharm Pharmacol. 1996; 48(11):1190-6. DOI: 10.1111/j.2042-7158.1996.tb03919.x. View

2.
DSouza R, Mutalik S, Venkatesh M, Vidyasagar S, Udupa N . Insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS PharmSciTech. 2005; 6(2):E184-9. PMC: 2750530. DOI: 10.1208/pt060227. View

3.
Ryan R, Elkind A, Baker C, MULLICAN W, DeBussey S, Asgharnejad M . Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997; 49(5):1225-30. DOI: 10.1212/wnl.49.5.1225. View

4.
Wadell C, Bjork E, Camber O . Permeability of porcine nasal mucosa correlated with human nasal absorption. Eur J Pharm Sci. 2003; 18(1):47-53. DOI: 10.1016/s0928-0987(02)00240-3. View

5.
Fowler P, Lacey L, Thomas M, Keene O, Tanner R, Baber N . The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991; 31(5):291-4. DOI: 10.1159/000116756. View